These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15538134)

  • 1. Reply to Dr. J-C Shim and colleagues regarding "Fluoxetine augmentation of haloperidol in chronic schizophrenia" [J Clin Psychopharmacol 2003;23:520-521].
    Mackin P; Young AH
    J Clin Psychopharmacol; 2004 Dec; 24(6):670. PubMed ID: 15538134
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluoxetine augmentation of haloperidol in chronic schizophrenia.
    Shim JC; Kelly DL; Kim YH; Yoon YR; Park JH; Shin JG; Conley RR
    J Clin Psychopharmacol; 2003 Oct; 23(5):520-2. PubMed ID: 14520132
    [No Abstract]   [Full Text] [Related]  

  • 3. Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient.
    D'Souza DC; Bennett A; Abi-Dargham A; Krystal JH
    J Clin Psychopharmacol; 1994 Oct; 14(5):361-3. PubMed ID: 7806697
    [No Abstract]   [Full Text] [Related]  

  • 4. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine.
    Goff DC; Midha KK; Brotman AW; Waites M; Baldessarini RJ
    Am J Psychiatry; 1991 Jun; 148(6):790-2. PubMed ID: 2035723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ; Lee JG; Kim YH
    J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.
    Sa AR; Hounie AG; Sampaio AS; Arrais J; Miguel EC; Elkis H
    Compr Psychiatry; 2009; 50(5):437-42. PubMed ID: 19683614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
    Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.
    Preskorn SH
    J Psychiatr Pract; 2008 Jan; 14(1):45-54. PubMed ID: 18212602
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to Shen J, Kobak K, Zhao Y, et al. Use of remote centralized raters via live 2-way video ina multicenter clinical trial for schizophrenia. (J Clin Psychopharmacol. 2008;28:691-693).
    Grunze HC; Höschl C; Montgomery SA; Sartorius N; Vieta E
    J Clin Psychopharmacol; 2009 Aug; 29(4):409; author reply 409-10. PubMed ID: 19593194
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluoxetine in chronic schizophrenia.
    Lindenmayer JP; Vakharia M; Kanofsky D
    J Clin Psychopharmacol; 1990 Feb; 10(1):76. PubMed ID: 2307741
    [No Abstract]   [Full Text] [Related]  

  • 12. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longterm maintenance therapy with depot haloperidol in schizophrenia.
    Zbytovský J
    Homeost Health Dis; 1991; 33(5-6):287. PubMed ID: 18265499
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine.
    Gama CS; Salvador M; Andreazza AC; Kapczinski F; Silva Belmonte-de-Abreu P
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):512-5. PubMed ID: 16426720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of phenobarbital and haloperidol in resistant schizophrenia.
    Prakash R; Reed RM; Bass AD
    J Clin Psychopharmacol; 1984 Dec; 4(6):362-3. PubMed ID: 6512009
    [No Abstract]   [Full Text] [Related]  

  • 17. No effect of haloperidol on cerebrospinal fluid acetylcholinesterase in patients with schizophrenia.
    Huff FJ; Reiter CT; Rosen J; Peters J; van Kammen DP
    Biol Psychiatry; 1988 Oct; 24(6):701-4. PubMed ID: 3167152
    [No Abstract]   [Full Text] [Related]  

  • 18. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions.
    Song F; Harvey I; Lilford R
    J Clin Epidemiol; 2008 May; 61(5):455-63. PubMed ID: 18394538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should the Physician's Desk Reference contraindicate the use of chlorpromazine-fluoxetine combination? A case report.
    Adetunji B; Basil B; Mathews M; Osinowo T
    J Clin Psychopharmacol; 2006 Aug; 26(4):438. PubMed ID: 16855470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.